BLI Banque de Luxembourg Investments Lowers Stock Position in Stryker Corporation $SYK

BLI Banque de Luxembourg Investments lowered its position in Stryker Corporation (NYSE:SYK) by 75.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 773 shares of the medical technology company’s stock after selling 2,360 shares during the period. BLI Banque de Luxembourg Investments’ holdings in Stryker were worth $274,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Claret Asset Management Corp increased its holdings in Stryker by 5.7% during the fourth quarter. Claret Asset Management Corp now owns 741 shares of the medical technology company’s stock worth $260,000 after buying an additional 40 shares during the last quarter. O Shaughnessy Asset Management LLC increased its holdings in Stryker by 1.2% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 54,142 shares of the medical technology company’s stock worth $19,029,000 after buying an additional 661 shares during the last quarter. CenterBook Partners LP increased its holdings in Stryker by 232.1% during the fourth quarter. CenterBook Partners LP now owns 2,122 shares of the medical technology company’s stock worth $746,000 after buying an additional 1,483 shares during the last quarter. Manchester Capital Management LLC increased its holdings in Stryker by 46.4% during the fourth quarter. Manchester Capital Management LLC now owns 3,727 shares of the medical technology company’s stock worth $1,310,000 after buying an additional 1,182 shares during the last quarter. Finally, Fiera Capital Corp increased its holdings in Stryker by 60.5% during the fourth quarter. Fiera Capital Corp now owns 46,278 shares of the medical technology company’s stock worth $16,265,000 after buying an additional 17,450 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

SYK opened at $314.41 on Wednesday. The company has a market capitalization of $120.53 billion, a price-to-earnings ratio of 36.39, a PEG ratio of 1.90 and a beta of 0.78. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The firm has a 50-day moving average price of $317.55 and a 200-day moving average price of $345.01. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $404.87.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). The business had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.Stryker’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities analysts expect that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be paid a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Insider Transactions at Stryker

In other news, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 5,220 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the transaction, the vice president owned 13,137 shares of the company’s stock, valued at $3,728,937.45. This trade represents a 28.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 323,264 shares of company stock worth $100,659,489 over the last quarter. Corporate insiders own 4.60% of the company’s stock.

Wall Street Analyst Weigh In

SYK has been the subject of a number of research analyst reports. Truist Financial restated a “hold” rating and set a $330.00 price objective (down from $380.00) on shares of Stryker in a report on Monday, May 4th. Robert W. Baird set a $385.00 price objective on shares of Stryker in a report on Friday, May 1st. BTIG Research decreased their price objective on shares of Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a report on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 price objective on shares of Stryker in a report on Friday, May 1st. Finally, Jefferies Financial Group restated a “buy” rating and set a $465.00 price objective on shares of Stryker in a report on Wednesday, March 4th. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $395.33.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.